Research shows chemotherapy has no negative effects on babies in utero
Research shows chemotherapy has no negative effects on babies in utero
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma
Nivolumab potentially superior to standard chemo in advanced melanoma
Targeted therapy for iodine-refractory thyroid cancer
Questions raised about the future of lung cancer vaccination?
PD-L1 protein a possible immunotherapy target in mesothelioma
Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib
Molecular targeting in cancer and the impact on personalised medicine
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer